CN101249287B - 一种治疗冠心病的血管支架 - Google Patents
一种治疗冠心病的血管支架 Download PDFInfo
- Publication number
- CN101249287B CN101249287B CN2008101035248A CN200810103524A CN101249287B CN 101249287 B CN101249287 B CN 101249287B CN 2008101035248 A CN2008101035248 A CN 2008101035248A CN 200810103524 A CN200810103524 A CN 200810103524A CN 101249287 B CN101249287 B CN 101249287B
- Authority
- CN
- China
- Prior art keywords
- blood vessel
- metal rack
- support
- side coating
- intravascular stent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 18
- 210000004204 blood vessel Anatomy 0.000 title claims description 120
- 239000011248 coating agent Substances 0.000 claims abstract description 112
- 238000000576 coating method Methods 0.000 claims abstract description 112
- 229910052751 metal Inorganic materials 0.000 claims abstract description 82
- 239000002184 metal Substances 0.000 claims abstract description 82
- 238000000034 method Methods 0.000 claims abstract description 26
- 238000003259 recombinant expression Methods 0.000 claims abstract description 22
- 229920006237 degradable polymer Polymers 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims description 53
- 102000058223 human VEGFA Human genes 0.000 claims description 53
- 208000037803 restenosis Diseases 0.000 claims description 38
- 239000007788 liquid Substances 0.000 claims description 32
- 238000002360 preparation method Methods 0.000 claims description 32
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 28
- 239000004626 polylactic acid Substances 0.000 claims description 28
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 28
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 24
- 229960002930 sirolimus Drugs 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 23
- 238000002156 mixing Methods 0.000 claims description 10
- 229920001244 Poly(D,L-lactide) Polymers 0.000 claims description 5
- 229910000831 Steel Inorganic materials 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 239000010959 steel Substances 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 3
- 229960001592 paclitaxel Drugs 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 229960005167 everolimus Drugs 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 229960001967 tacrolimus Drugs 0.000 claims description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 2
- YYSFXUWWPNHNAZ-PKJQJFMNSA-N umirolimus Chemical group C1[C@@H](OC)[C@H](OCCOCC)CC[C@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 YYSFXUWWPNHNAZ-PKJQJFMNSA-N 0.000 claims description 2
- 229950009819 zotarolimus Drugs 0.000 claims description 2
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 17
- 229920000642 polymer Polymers 0.000 abstract description 13
- 230000002792 vascular Effects 0.000 abstract description 11
- 108090000623 proteins and genes Proteins 0.000 abstract description 10
- 230000004663 cell proliferation Effects 0.000 abstract description 9
- 210000000329 smooth muscle myocyte Anatomy 0.000 abstract description 7
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 210000002950 fibroblast Anatomy 0.000 abstract description 4
- 239000013604 expression vector Substances 0.000 abstract 1
- 210000003725 endotheliocyte Anatomy 0.000 description 30
- 241000282472 Canis lupus familiaris Species 0.000 description 28
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 25
- 239000013612 plasmid Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 16
- 238000004140 cleaning Methods 0.000 description 15
- 210000002808 connective tissue Anatomy 0.000 description 14
- 239000007943 implant Substances 0.000 description 14
- 239000011247 coating layer Substances 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 210000003038 endothelium Anatomy 0.000 description 12
- 238000004880 explosion Methods 0.000 description 12
- 238000012545 processing Methods 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 238000007689 inspection Methods 0.000 description 10
- 230000002980 postoperative effect Effects 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 8
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 8
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 8
- 102000013275 Somatomedins Human genes 0.000 description 8
- 229940126864 fibroblast growth factor Drugs 0.000 description 8
- 238000002513 implantation Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 210000003556 vascular endothelial cell Anatomy 0.000 description 8
- 208000005156 Dehydration Diseases 0.000 description 7
- 230000018044 dehydration Effects 0.000 description 7
- 238000006297 dehydration reaction Methods 0.000 description 7
- 230000005540 biological transmission Effects 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 206010020718 hyperplasia Diseases 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 238000004043 dyeing Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 206010020880 Hypertrophy Diseases 0.000 description 4
- 108091005975 Myofilaments Proteins 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 210000003850 cellular structure Anatomy 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000007654 immersion Methods 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 210000003632 microfilament Anatomy 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 210000000110 microvilli Anatomy 0.000 description 4
- 210000003470 mitochondria Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000004575 stone Substances 0.000 description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000001168 carotid artery common Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000007598 dipping method Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000001732 thrombotic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- 101100008050 Caenorhabditis elegans cut-6 gene Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 240000000594 Heliconia bihai Species 0.000 description 2
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- 241001116500 Taxus Species 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 239000002662 enteric coated tablet Substances 0.000 description 2
- 210000000222 eosinocyte Anatomy 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 201000011066 hemangioma Diseases 0.000 description 2
- 210000003677 hemocyte Anatomy 0.000 description 2
- 229940000351 hemocyte Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000003448 neutrophilic effect Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- AHDSRXYHVZECER-UHFFFAOYSA-N 2,4,6-tris[(dimethylamino)methyl]phenol Chemical compound CN(C)CC1=CC(CN(C)C)=C(O)C(CN(C)C)=C1 AHDSRXYHVZECER-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 1
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 1
- 102000004240 Glycodelin Human genes 0.000 description 1
- 108010081520 Glycodelin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000002586 coronary angiography Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- UONOETXJSWQNOL-UHFFFAOYSA-N tungsten carbide Chemical compound [W+]#[C-] UONOETXJSWQNOL-UHFFFAOYSA-N 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Landscapes
- Media Introduction/Drainage Providing Device (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101035248A CN101249287B (zh) | 2008-04-08 | 2008-04-08 | 一种治疗冠心病的血管支架 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101035248A CN101249287B (zh) | 2008-04-08 | 2008-04-08 | 一种治疗冠心病的血管支架 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101249287A CN101249287A (zh) | 2008-08-27 |
CN101249287B true CN101249287B (zh) | 2010-08-04 |
Family
ID=39952994
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008101035248A Active CN101249287B (zh) | 2008-04-08 | 2008-04-08 | 一种治疗冠心病的血管支架 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101249287B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108295316A (zh) * | 2018-03-08 | 2018-07-20 | 戴庆涛 | 一种肠道支架及其制作方法 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101361988B (zh) * | 2008-09-12 | 2011-12-21 | 西南交通大学 | 一种具有生物相容性的血管支架或心脏瓣膜表面涂层的制备方法 |
WO2010043177A1 (zh) * | 2008-10-15 | 2010-04-22 | Zhou Xing | 生物诱导型人体腔管代用品 |
KR101166885B1 (ko) * | 2010-04-21 | 2012-07-18 | 주식회사 엠아이텍 | 듀얼 코팅 구조의 혈관용 스텐트 |
CN101972181B (zh) * | 2010-11-12 | 2013-08-28 | 上海交通大学医学院附属新华医院 | 一种生物可吸收支架 |
CN102579097A (zh) * | 2012-02-15 | 2012-07-18 | 北京航空航天大学 | 一种覆膜支架 |
CN106562838A (zh) * | 2015-10-09 | 2017-04-19 | 李道远 | 一种新型心血管支架 |
CN112505319A (zh) * | 2020-10-26 | 2021-03-16 | 绍兴梅奥心磁医疗科技有限公司 | 一种待检标志物免疫定量检测装置、检测方法及用途 |
CN113288533A (zh) * | 2021-05-11 | 2021-08-24 | 天津市胸科医院 | 一种可吸收支架控制系统、控制方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1312635A2 (en) * | 2000-03-18 | 2003-05-21 | Polyzenix GmbH | Dental implants having bacterial resistance |
CN101091806A (zh) * | 2006-06-20 | 2007-12-26 | 天津市凯迪亚医疗器械有限公司 | 冠脉支架可降解药物缓释涂层 |
-
2008
- 2008-04-08 CN CN2008101035248A patent/CN101249287B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1312635A2 (en) * | 2000-03-18 | 2003-05-21 | Polyzenix GmbH | Dental implants having bacterial resistance |
CN101091806A (zh) * | 2006-06-20 | 2007-12-26 | 天津市凯迪亚医疗器械有限公司 | 冠脉支架可降解药物缓释涂层 |
Non-Patent Citations (1)
Title |
---|
冯博.国产外周动脉雷帕霉素-肝素洗脱支架预防再狭窄研究.中国医科大学博士学位论文.2007,全文. * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108295316A (zh) * | 2018-03-08 | 2018-07-20 | 戴庆涛 | 一种肠道支架及其制作方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101249287A (zh) | 2008-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101249287B (zh) | 一种治疗冠心病的血管支架 | |
Wen et al. | Local delivery of dual microRNAs in trilayered electrospun grafts for vascular regeneration | |
US20200246126A1 (en) | Biodegradable vascular grafts | |
Gupta et al. | Tissue‐engineered vascular grafts: emerging trends and technologies | |
Kumar et al. | Acellular vascular grafts generated from collagen and elastin analogs | |
de Valence et al. | Plasma treatment for improving cell biocompatibility of a biodegradable polymer scaffold for vascular graft applications | |
Alessandrino et al. | Three-layered silk fibroin tubular scaffold for the repair and regeneration of small caliber blood vessels: from design to in vivo pilot tests | |
Wang et al. | Heparin and vascular endothelial growth factor loaded poly (L-lactide-co-caprolactone) nanofiber covered stent-graft for aneurysm treatment | |
Wang et al. | Functionalization of electrospun poly (ε-caprolactone) scaffold with heparin and vascular endothelial growth factors for potential application as vascular grafts | |
Tan et al. | Bioactive materials facilitating targeted local modulation of inflammation | |
US20100221304A1 (en) | Bionanocomposite Materials and Methods For Producing and Using the Same | |
Wu et al. | Design and fabrication of a biomimetic vascular scaffold promoting in situ endothelialization and tunica media regeneration | |
JP2015513349A (ja) | 組織修復のための基礎材システム | |
Ostdiek et al. | An in vivo study of a gold nanocomposite biomaterial for vascular repair | |
Shen et al. | 3D printed personalized, heparinized and biodegradable coronary artery stents for rabbit abdominal aorta implantation | |
Fang et al. | Fabrication of heparinized small diameter TPU/PCL bi-layered artificial blood vessels and in vivo assessment in a rabbit carotid artery replacement model | |
Hui et al. | Preparation and in vivo evaluation of surface heparinized small diameter tissue engineered vascular scaffolds of poly (ε-caprolactone) embedded with collagen suture | |
Zhang et al. | Polycaprolactone/gelatin degradable vascular grafts simulating endothelium functions modified by nitric oxide generation | |
Tanaka et al. | Evaluation of small-diameter silk vascular grafts implanted in dogs | |
Madhavan et al. | Performance of marrow stromal cell-seeded small-caliber multilayered vascular graft in a senescent sheep model | |
Nan et al. | Tantalum and magnesium nanoparticles enhance the biomimetic properties and osteo-angiogenic effects of PCL membranes | |
Lee et al. | A comparative study of an anti-thrombotic small-diameter vascular graft with commercially available e-ptfe graft in a porcine carotid model | |
Liu et al. | Development of a decellularized human amniotic membrane-based electrospun vascular graft capable of rapid remodeling for small-diameter vascular applications | |
Yamamoto et al. | Rapid endothelialization and thin luminal layers in vascular grafts using silk fibroin | |
Dong et al. | Micro-nanofiber composite biomimetic conduits promote long-gap peripheral nerve regeneration in canine models |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANDONG JIWEI MEDICAL PRODUCTS CO., LTD. Free format text: FORMER OWNER: ZHANG YUXIAO Effective date: 20101124 Free format text: FORMER OWNER: WANG JICHENG |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100001 BEIJING 301 HOSPITAL, NO.28, FUXING ROAD, HAIDIAN DISTRICT, BEIJING TO: 264200 NO.328, SHICHANG AVENUE, WEIHAI CITY, SHANDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20101124 Address after: 328 No. 264200 Shandong city of Weihai province Shichang Road Patentee after: XTENT, INC. Address before: 28 Beijing 301 Hospital, Fuxing Road, Beijing, Haidian District 100001, China Co-patentee before: Wang Jicheng Patentee before: Zhang Yuxiao |
|
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 264200 Dalian Road, Weihai high tech Industrial Development Zone, Shandong, China, No. 68 Patentee after: XTENT, INC. Address before: 328 No. 264200 Shandong city of Weihai province Shichang Road Patentee before: XTENT, INC. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Blood vessel support for curing coronary heart disease Effective date of registration: 20160930 Granted publication date: 20100804 Pledgee: Bank of China Singapore Branch Pledgor: XTENT, INC. Registration number: 2016990000854 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20191218 Granted publication date: 20100804 Pledgee: Bank of China Singapore Branch Pledgor: XTENT, INC. Registration number: 2016990000854 |